Generally, the c-peptide level in a man or woman is between 0.5 and 2.0. If you have high levels of this peptide, you have an increased risk of developing a number of microvascular complications. But if you have low levels of this peptide, you have a greater chance of developing a number of macrovascular complications.
Normal range for the c-peptide level for a man or woman is between 0.5 and 2.0
Usually, a C-peptide test involves collecting blood or urine for analysis. This can be performed by a healthcare provider or by a lab technician. The results may take up to five days to be returned. The test will help the physician determine the type of diabetes you have. It can also help monitor the treatment of your disease.
a post on the Regenics`s blog for the c-peptide level in a man or woman is 0.5 to 2.0 nanograms per milliliter of blood. The higher your level of C-peptide, the more insulin your body produces. If your body produces too much insulin, your blood glucose levels will be high. If your body does not produce enough insulin, you will be hypoglycemic (low blood sugar).
Depending on the reason for the test, you may be asked to fast for up to 12 hours or to stop taking medications before the test. Some physicians will ask you to stop taking vitamin B7 (biotin) supplements for 24 hours before the test.
It may identify patients with ketoacidosis
Using a blood test to measure c-peptide levels in urine may be the next big thing in diabetic medicine. https://www.google.com/maps?cid=3424385977669420479 has been shown to inhibit endothelial cell ROS formation in hyperglycemia, and it may be a useful tool in the diagnostic toolbox.
However, the c-peptide test is not recommended for routine use. Its accuracy in patients with chronic kidney disease may be suspect. It is also a time consuming process. Lastly, the quantity of c-peptide excreted in the urine is indicative of 5 to 10 percent of the pancreatic c-peptide production. This means that the average patient is receiving more of the c-peptide novelty than their health care provider is telling them.
In addition to being a clinically relevant test, the c-peptide may have a role to play in future diabetes guidelines. For example, it may be a suitable screen for diabetes patients at high risk for complications, as well as for identifying rare forms of primary diabetes.
It’s associated with increasing microvascular complications when low and macrovascular complications when high
Despite its potential as a marker for future clinical outcomes, c-peptide has not been widely used in the clinical setting. This review outlines current knowledge of the molecule and identifies how its measurement might prove to be useful in clinical practice.
The most common uses for c-peptide in diabetes include identifying patients at risk for hypoglycemia, monitoring the effectiveness of subcutaneous insulin, and assessing the risk of microvascular complications. Its role as a marker is largely unclear, but its presence in clinical trials suggests a possible correlation with the onset of diabetes and its complications.
A preliminary randomized controlled trial suggests that subcutaneous c-peptide therapy may improve autonomic nerve dysfunction in type 2 diabetes. The efficacy of the treatment may also be reflected in the reduction in albuminuria, the earliest sign of diabetic kidney disease.
The c-peptide is also known to decrease the rate of leukocyte adhesion to the walls of endothelial cells in hyperglycemia, thus preventing early stages of atherosclerosis plaque formation. The presence of c-peptide also indicates that a person has better metabolic control, a key component in managing type 2 diabetes.
Obesity may interfere with accurate c-peptide evaluation
Despite the increasing popularity of C-peptide measurement in clinical practice, there are still a number of unresolved issues related to its use. The current evidence base summarizes its potential value. However, future studies are needed to further assess its role in daily clinical practices and identify the specific areas of uncertainty. In the case of pediatric patients, it may also help in identifying early signs of insulin resistance. In addition, C-peptide measurement may also be useful in longitudinal follow-up of certain populations.
The results of the study suggest that obesity may interfere with the accurate measurement of C-peptide. In obese individuals, insulin and C peptide are produced in large amounts, and the kidneys eliminate these substances from the body. This can make it difficult to accurately evaluate these markers in patients with diabetes. This can be especially true for those who are under constant insulin therapy.
In order to ensure an accurate evaluation of C-peptide, it is important to consider other factors that can interfere with the test, such as concomitant blood glucose and kidney function. The study suggested that the association between C-peptide and breast cancer mortality was stronger in women with higher BMI.
18133 Ventura Blvd Suite C, Tarzana, CA 91356